Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 935-938

  Deguchi, H ^a   Bouma, B N ^a,b   Middeldorp, S ^c   Lee, Y M ^a   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activated protein C; APC resistance; Glucosylceramide; Oral contraceptive; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; CONTRACEPTIVE AGENT; ESTRADIOL; GLUCOSYLCERAMIDE; DESOGESTREL; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTRACEPTION; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS; VEIN THROMBOSIS; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; PILOT STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY;

ACTIVATED PROTEIN C RESISTANCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; GLUCOSYLCERAMIDES; HUMANS; LEVONORGESTREL; PILOT PROJECTS; PROTEIN C; PROTEIN S; PROTHROMBIN TIME; RISK; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOSIS;

EID: 23844558299     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01335.x     Document Type: Article

References (22)

1. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2: 1165-8.
2. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-62.
3. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
4. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
5. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
6. Zivelin A, Gitel S, Griffin JH, Xu X, Fernandez JA, Martinowitz U, Cohen Y, Halkin H, Seligsohn U, Inbal A. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-901.
7. Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers J, Bouma BN, Buller H, Prins M, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C. Lancet 1999; 354: 2036-40.
8. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 2001; 323: 1-9.
9. Rosendaal FR, van Hylckama Vlieg A, Tains BC, Helmerhorst FM. Estrogen, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-80.
10. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
11. Fernandez JA, Kojima K, Petaja J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis 2000; 26: 115-23.
12. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97: 1907-14.
13. Deguchi H, Fernandez JA, Griffin JH. Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. J Biol Chem 2002; 277: 8861-5.
14. Yegneswaran S, Deguchi H, Griffin JH. Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human and bovine activated protein C with negatively charged phospholipid vesicles. J Biol Chem 2003; 278: 14614-21.
15. Shukla A, Shukla GS, Radin NS. Control of kidney size by sex hormones: possible involvement of glucosylceramide. Am J Physiol 1992; 262: F24-9.
16. Cheung MC, Walden CE, Knopp RH. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. Metabolism 1999; 48: 658-64.
17. Kemmeren JM, Algra A, Grobbee DE. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 2001; 250: 441-8.
18. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63: 1-11.
19. Oyelola OO, Thomas KD, Olusi SO. Steroidal contraceptives and changes in individual plasma phospholipids: possible role in thrombosis. Adv Contracept 1990; 6: 193-206.
20. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
21. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
22. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent downregulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.